Keyuan Pharma: Received the "Decision on Not Implementing Further Review of Antitrust Review of Operator Concentration" from the State Administration for Market Regulation

Keyuan Pharma announced that the company intends to acquire 99.42% equity of Shandong Hongjitang Pharmaceutical Group Co., Ltd. through the issuance of shares, while also raising matching funds. This transaction has received the "Decision on Not Implementing Further Review of Operator Concentration Antitrust Review" issued by the State Administration for Market Regulation, which decides not to implement further review. This transaction still needs to go through the approval of the Shenzhen Stock Exchange and registration with the China Securities Regulatory Commission, and there is uncertainty regarding its final success